UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of the ~~Report~~Securities ~~(Date~~Exchange Act of ~~earliest event reported): March 16, 2026~~1934

~~DARE~~Date ~~BIOSCIENCE~~of Report (Date of earliest event reported): March 26, ~~INC.~~2026

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Dare Bioscience, Inc

Delaware

001-36395

20-4139823

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3 2.02 ~~Unregistered~~Results ~~Sales~~ of ~~Equity~~Operations ~~Securities~~and Financial Condition.

On March 1626, 2026, Daré Bioscience, Inc. (~~“Daré” “we,” “us,” or “our”) completed a closing of our previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively~~ the “~~Investor Units~~Company”), ~~each~~issued ~~consisting~~a ofpress ~~one~~release ~~share~~announcing ofits ~~Series~~financial Aresults ~~Convertible Preferred Stock (the “Series A Preferred~~for ~~Stock”) and two warrants, each to purchase one share of our common stock (“Investor Warrants”), with each Investor Unit being offered at an offering price of $5.00 (~~the ~~“Offering”).~~year Inended ~~connection~~December ~~therewith~~31, ~~we issued an aggregate of 43~~2025,~~050 Investor~~ ~~Units~~a ~~consisting~~copy of ~~43,050~~which ~~shares~~is offurnished ~~Series~~as AExhibit ~~Preferred~~99.1 ~~Stock and Investor Warrants~~ to ~~purchase~~this ~~up to 86,100 shares of our common stock~~report.

The ~~offering~~information ofin ~~the~~this ~~Investor~~Item ~~Units~~2.02 isand ~~being~~in ~~conducted~~Exhibit ~~pursuant~~99.1 to ~~our~~this ~~offering~~report ~~statement~~is onbeing ~~Form~~furnished ~~1-A~~and ~~(File~~shall ~~No.~~not ~~024-12688),~~be asdeemed ~~amended,~~to ~~which~~be “filed” ~~was~~for ~~qualified~~purposes byof ~~the~~Section ~~U.S.~~18 ~~Securities~~of ~~and~~the Securities Exchange ~~Commission~~Act of 1934, as amended (the “~~SEC~~Exchange Act”), onor ~~January~~otherwise 5,subject to ~~2026,~~the ~~and~~liabilities ~~the~~of ~~offering~~that ~~circular~~section, ~~dated January~~nor 6,shall ~~2026,~~such ~~which~~information ~~forms~~be adeemed ~~part~~to ~~thereof.~~be ~~Additional~~incorporated ~~information~~by ~~regarding~~reference ~~the~~into ~~Offering~~any ~~and~~filing under the ~~terms~~Exchange Act ofor ~~conversion~~the ~~and~~Securities ~~exercise~~Act of ~~the~~ ~~Series~~1933, Aas ~~Preferred~~amended, ~~Stock~~whether ~~and~~made ~~Investor~~before ~~warrants~~or ~~was~~after ~~previously~~the ~~reported~~date inhereof, ~~our~~regardless ~~Current~~of ~~Report~~any ongeneral ~~Form~~incorporation by ~~8-K~~reference ~~filed~~language ~~with~~in ~~the~~any ~~SEC~~such ~~on January 29~~filing, ~~2026,~~except ~~and~~as isthe ~~incorporated~~Company ~~herein~~expressly sets forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued on March 26, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DARÉ BIOSCIENCE, INC.
Dated: March 17, 2026	By:	/s/ Sabrina Martucci Johnson
Dated: March 26, 2026	By:	/s/ Sabrina Martucci Johnson
	Name:	Sabrina Martucci Johnson
	Title:	President and Chief Executive Officer

-3-

Filing Compare · Dare Bioscience, Inc.